OCON Therapeutics

OCON Therapeutics develops innovative and safe intra-uterine medical solutions that are inspired by womens bodies and anatomy, to better the lives of women everywhere. In the past decade we have developed the IUBTM platform, our proprietary intrauterine ball-shaped technology, utilising super-elastic alloy Nitinol to carry long lasting hormone-free contraception and other drugs. OCONs first product, the IUBTM Ballerine, is a CE approved copper-based hormone-free intrauterine contraceptive, effective for up to 5 years, and already in use by over 100,000 women in 24 countries, including EU member countries, South Africa and Israel. The Company is currently enlisting patients for its phase...

'women''s health,contraception,intrauterine,gynecology,iud,iub,ballerine,drug products,ball contraception,innovative contraception,obgyn,larc,aub,gp,the sead,women''s lifestyle,healthcare,abnormal uterine bleeding,hysterectomy,non surgical therapy,bio investments,non-hormonal contraception,sexual health,baby planning,hormone-free contraception,birth control,and family planning'

Ocon therapeutics's revenue is 11m - 100m

Ocon therapeutics has 11 - 50 employees.